Mert Oztas

Mert Oztas

Auto-generated profile, based on publicly available information

Mert Oztas

Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Acibadem University , Istanbul

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2021 in Rheumatology International
Verified
Journal Article
Open access
PDF file
BYBerna Yurttas
Berna Yurttas
BPBurc Cagri Poyraz
Burc Cagri Poyraz
NSNecdet Sut
Necdet Sut
AOAyse Ozdede
Ayse Ozdede
MOMert Oztas
Mert Oztas
ESEmire Seyahi
Emire Seyahi
Objectives Vaccination against COVID-19 emerges as an effective strategy for combating the pandemic. While many of our patients with rheumatic diseases (RD) wonder whether it is safe to get the vaccine, vaccine hesitancy is rising among the general population. We assessed the willingness to get vaccination and its probable predictors among patients with RD compared to healthcare workers and a sample from the general population. Methods We conducted a web-based questionnaire survey in a cross-sectional design in 3 groups of participants just before the mass vaccination program in Istanbul, Turkey. The questionnaire sought socio-demographic variables, COVID-19 related risk factors, willingness to get vaccination, and concerns and thoughts about vaccine. COVID-19 anxiety scale (CAS) was also evaluated. Results We studied in total 732 patients with RD (Group 1), 763 individuals representing general population (Group 2) and 320 hospital workers (Group 3). Dysfunctional anxiety related to COVID-19 was found in 4.9%, 3.8% and 4.1%, in Group 1, 2 and 3, respectively. Of the patients with RD, 29.2% were willing to be vaccinated, 19.0% were unwilling and 51.8% were undecided. These were somewhat similar among the general population (yes: 34.6%, no: 23.3% and unsure: 42.1%), with significantly less undecided individuals (p < 0.001). On the other hand, hospital workers were significantly more willing (yes: 52.5%, no: 20.9% and unsure: 26.6%) (p < 0.001). Main concerns were probable side effects, unknown scientific results and having no trust. Being male, older age, working in a hospital, not having contracted COVID-19 and high scores on CAS were found to be independently associated with willingness. Conclusions The low rate of vaccine acceptance among patients with RD, as well as general population sampling is worrying. Healthcare policies should aim to implement communication, promote confidence and increase demand for COVID-19 vaccine.

9 June 2021 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
ESEmire Seyahi
Emire Seyahi
GBGuldaran Bakhdiyarli
Guldaran Bakhdiyarli
MOMert Oztas
Mert Oztas
MKMert Ahmet Kuskucu
Mert Ahmet Kuskucu
YTYeşim Tuyji Tok
Yeşim Tuyji Tok
VHVedat Hamuryudan
Vedat Hamuryudan

9 July 2020 in Internal and Emergency Medicine
Verified
Journal Article
Closed access
PDF file
BYBerna Yurttaş
Berna Yurttaş
MOMert Oztas
Mert Oztas
ATAli Tunc
Ali Tunc
IBİlKer İnAnç Balkan
İlKer İnAnç Balkan
OTOmer Fehmi Tabak
Omer Fehmi Tabak
ESEmire Seyahi
Emire Seyahi

25 February 2017 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
MOMert Oztas
Mert Oztas
SUSerdal Ugurlu
Serdal Ugurlu
OAOvgu Aydin
Ovgu Aydin

25 November 2021 in Rheumatology International
Verified
Journal Article
Open access
PDF file
GOGuzin Ozcifci
Guzin Ozcifci
TATahacan AYDIN
Tahacan AYDIN
ZAZeynep Atli
Zeynep Atli
IBIlker Inanc Balkan
Ilker Inanc Balkan
FTFehmi Tabak
Fehmi Tabak
ESEmire Seyahi
Emire Seyahi
Initial case series of small number of patients at the beginning of the pandemic reported a rather guarded prognosis for Behçet’s syndrome (BS) patients infected with SARS-CoV-2. In this prospective study, we describe the incidence, clinical characteristics, disease course, management, and outcome in a large cohort of BS patients with laboratory-confirmed infection of SARS-CoV-2. We defined a cohort of 1047 registered BS patients who were aged between 16 and 60 years and seen routinely before the pandemic at the multidisciplinary outpatient clinic. We followed prospectively this cohort from beginning of April 2020 until the end of April 2021. During 13 months of follow-up, of the 1047 (599 M/448 F) patients, 592 (56.5%) were tested for SARS-CoV-2 PCR at least once and 215 (20.5%; 95% CI 0.18–0.23) were tested positive. We observed 2 peaks which took place in December 2020 and April 2021. Of the 215 PCR positive patients, complete information was available in 214. Of these 214, 14 (6.5%) were asymptomatic for COVID-19. In the remaining, the most common symptoms were anosmia, fatigue, fever, arthralgia, and headache. A total of 40 (18.7%) had lung involvement, 25 (11.7%) were hospitalized, 1 was admitted to the intensive care unit while none died. Favipiravir was the most prescribed drug (74.3%), followed by colchicine (40.2%), and hydroxychloroquine (20.1%) in the treatment of COVID-19. After COVID-19, 5 patients (2.3%) were given supplemental O2 and 31 (14.5%) antiaggregant or anticoagulants. During COVID-19, of the 214 PCR positive patients, 116 (54.2%) decreased the dose of their immunosuppressives or stopped taking completely; 36 (16.8%) experienced a BS flare which was mostly oral ulcers (10.3%). None of the patients reported a thrombotic event. A total of 93 (43.5%) patients reported BS flares after a median 45 days of COVID-19 infection and this was found to be significantly associated with immunosuppressive drug discontinuation. Multiple regression analysis adjusted for age and gender indicated that smoking and using interferon-alpha decreased the likelihood of getting COVID-19. The incidence and severity of COVID-19 did not differ between those who were using colchicine or not. The cumulative incidence of COVID-19 in this prospectively followed cohort of BS patients was almost two folds of that estimated for the general population living in Istanbul, Turkey, however, the clinical outcome of COVID-19 was not severe and there was no mortality. The protective effect of smoking and interferon deserves further investigation. On the other hand, colchicine did not have any positive or negative effect against COVID-19. Significant number of patients flared after COVID-19, however, this was significantly associated with immunosuppressive discontinuation during the infection. Contrary to our previous observations, COVID-19 did not seem to exacerbate thrombotic events during or after the infection.

1 October 2025 in Best Practice & Research Clinical Rheumatology
Verified
Journal Article
Closed access
TGTania Gudu
Tania Gudu
MOMert Oztas
Mert Oztas
Elena NikiphorouElena Nikiphorou
Elena Nikiphorou